Silence Therapeutics plc (SLN) Institutional Ownership

Ownership Summary

The institutional landscape for Silence Therapeutics plc (NASDAQ:SLN) includes 54 filers as of the latest reporting cycle ending September 2025.

• These investors collectively held 13.9% of the company's total shares outstanding in September 2025, down from 14.0% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by -0.02%, with a year-over-year a decrease of 20.59% in the count of filers.
• During the quarter, 18 institutions bought more Silence Therapeutics shares, 19 sold shares, and 17 of the 54 total investors held their position steady.
• The total number of shares held by institutions in Silence Therapeutics decreased to 19.70Mn as of September 2025, a net change of down by 3.91K shares quarter on quarter, and down 8.32Mn shares year over year.
• With 3.03Mn shares, TCG Crossover Management, LLC commands the largest institutional position in Silence Therapeutics as of September 30, 2025, equating to 2.14% of the company.
• Among the most significant buyers of Silence Therapeutics during September 2025 were MILLENNIUM MANAGEMENT LLC (99.86K), UBS Group AG (78.85K), Ikarian Capital, LLC (27.22K), BOOTHBAY FUND MANAGEMENT, LLC (27.22K), CANTOR FITZGERALD, L. P. (12.27K).
• Leading sellers of Silence Therapeutics stock in September 2025 included BlackRock, Inc. (106.40K), MARSHALL WACE, LLP (92.64K), CITADEL ADVISORS LLC (40.94K), WEXFORD CAPITAL LP (19.44K), ACADIAN ASSET MANAGEMENT LLC (7.93K).
• The top 10 institutional holders of Silence Therapeutics for the quarter ending September 2025 included TCG Crossover Management, LLC (3.03Mn), Siren, L.L.C. (2.91Mn), Redmile Group, LLC (2.16Mn), Lombard Odier Asset Management (USA) Corp (1.84Mn), MORGAN STANLEY (1.21Mn), Vivo Capital, LLC (1.11Mn), Nantahala Capital Management, LLC (1.04Mn), Frazier Life Sciences Management, L.P. (970.13K), Nextech Invest, Ltd. (952.40K), Ikarian Capital, LLC (900.78K).